Pharma Journalist -

Novo Nordisk unveiled new findings from its OASIS 4 Phase 3 trial at ObesityWeek® 2025 in Atlanta, reinforcing the potential of oral semaglutide 25 mg as a treatment option for adults…
Read More...

Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) has approved DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) as a single-agent therapy for adults…
Read More...

Jupiter Neurosciences, Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to initiate a Phase 2a clinical trial…
Read More...

Leukogene Therapeutics Inc. (LTI), a biopharmaceutical company focused on developing next-generation immunotherapies for blood and solid cancers, announced that the U.S. Food and Drug…
Read More...

Pacira BioSciences, Inc. has announced an exclusive worldwide license and collaboration agreement with AmacaThera to develop and commercialize AMT-143, a novel long-acting formulation…
Read More...

Merck, known as MSD outside the U.S. and Canada, has entered into a $700 million funding agreement with Blackstone Life Sciences to support the development of sacituzumab tirumotecan…
Read More...

Avant Technologies Inc., a Nevada-based corporation, and Singapore-based biotechnology firm SGAustria Pte. Ltd. have announced a Joint Venture and License Agreement to pioneer…
Read More...

Cencora, a leading global pharmaceutical solutions company, has announced plans to invest $1 billion through 2030 to strengthen and expand its pharmaceutical distribution network across…
Read More...

Eli Lilly and Company has announced plans to invest $3 billion in a new state-of-the-art manufacturing facility in Katwijk, the Netherlands, located within the Leiden Bio Science Park.…
Read More...

UCB, a global biopharmaceutical company, has received U.S. Food and Drug Administration (FDA) approval for KYGEVVI, a treatment for adults and pediatric patients suffering from…
Read More...